EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

PSMA PET in Lymph Node Staging of Prostate Cancer: From Diagnostic Accuracy to Clinical Decision-Making

Francesco Esperto iD, Arianna Pischetola iD, Matteo Bauckneht iD, Jacopo Passoni iD, Antonio Testa, Stefania Ferretti iD, Stefano Puliatti iD, Sebastiano Buti iD, Roberto Mario Scarpa iD, Davide Campobasso iD, Rocco Papalia iD

Cancers · 27.06.2026 · 18 (13) · 2094

DOI: 10.3390/cancers18132094 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 27.06.2026. Verfasst von Francesco Esperto und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Fondazione Policlinico Universitario Campus Bio-Medico of Rome, 00128 Rome, Italy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 91 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lymph node involvement in prostate cancer has major prognostic and therapeutic implications, yet conventional imaging based on size and morphology remains limited in detecting small-volume metastatic disease. Although extended pelvic lymph node dissection is considered the reference standard for nodal staging, it is invasive, associated with morbidity, and primarily diagnostic in intent. Prostate-specific membrane antigen positron emission tomography (PSMA PET) has reshaped staging by enabling molecular detection of nodal metastases, consistently demonstrating superior accuracy compared with conventional imaging. This narrative review critically evaluates the role of PSMA PET in lymph node staging, with a primary focus on primary diagnosis and selected considerations on biochemical recurrence, focusing not only on diagnostic accuracy but on clinical utility and decision-making. PSMA PET shows high specificity but moderate sensitivity for pelvic nodal metastases, with reduced performance for micrometastatic disease; therefore, a negative scan cannot reliably exclude nodal involvement in high-risk patients. Evidence indicates frequent stage migration and management changes, including refinement of surgical planning, radiotherapy target delineation, and treatment intensification strategies. However, most pivotal therapeutic trials were based on conventional imaging, and long-term outcome data validating PSMA PET-guided treatment adaptations remain limited. We discuss biological rationale, radiotracer characteristics, interpretation frameworks, guideline perspectives, real-world variability in adoption, and current limitations, including false-positive findings, PSMA heterogeneity, and lack of universal standardization. Rather than replacing established staging paradigms, PSMA PET should be integrated within a comprehensive, risk-adapted framework. Ongoing prospective trials will clarify whether molecularly defined nodal staging translates into improved oncologic outcomes and will determine its definitive role in contemporary prostate cancer management.

Schlagwörter

Stichwörter der Autor:innen

PSMA PETlymph node stagingprostate cancer

Autor:innen und Institutionen

  • Department of Urology, Fondazione Policlinico Universitario Campus Bio-Medico of Rome, 00128 Rome, Italy.
  • Research Unit of Urology, Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, Via Alvaro del Portillo 21, 00128 Roma, Italy.
  • Nuclear Medicine, Department of Health Sciences (DISSAL), University of Genova, 16132 Genova, Italy.
  • IRCCS Azienda Ospedaliera Metropolitana, 16132 Genova, Italy.
  • Department of Urology, San Camillo De Lellis Hospital, ASL of Rieti, 02100 Rome, Italy.
  • Urology Unit, Azienda Ospedaliero-Universitaria of Modena, University of Modena and Reggio Emilia, 41125 Modena, Italy.

ORCID-Profile: Francesco Esperto, Arianna Pischetola, Matteo Bauckneht, Jacopo Passoni, Stefania Ferretti, Stefano Puliatti, Sebastiano Buti, Roberto Mario Scarpa, Davide Campobasso, Rocco Papalia

Zitieren

APA

Esperto, F., Pischetola, A., Bauckneht, M., Passoni, J., Testa, A., Ferretti, S., Puliatti, S., Buti, S., Scarpa, R. M., Campobasso, D., & Papalia, R. (2026). PSMA PET in Lymph Node Staging of Prostate Cancer: From Diagnostic Accuracy to Clinical Decision-Making. Cancers, 18(13), 2094. https://doi.org/10.3390/cancers18132094

Vancouver

Esperto F, Pischetola A, Bauckneht M, Passoni J, Testa A, Ferretti S, et al. PSMA PET in Lymph Node Staging of Prostate Cancer: From Diagnostic Accuracy to Clinical Decision-Making. Cancers. 2026;18(13):2094. doi:10.3390/cancers18132094

BibTeX
@article{Esperto2026,
  author = {Esperto, Francesco and Pischetola, Arianna and Bauckneht, Matteo and Passoni, Jacopo and Testa, Antonio and Ferretti, Stefania and Puliatti, Stefano and Buti, Sebastiano and Scarpa, Roberto Mario and Campobasso, Davide and Papalia, Rocco},
  title = {PSMA PET in Lymph Node Staging of Prostate Cancer: From Diagnostic Accuracy to Clinical Decision-Making},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {13},
  pages = {2094},
  doi = {10.3390/cancers18132094}
}
Kostenlos starten →